View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 15, 2022

Moderna reports dosing of first subject in Phase I HIV trimer vaccine trial

The trial will analyse the safety and immunogenicity of the vaccines in nearly 100 HIV-negative adults of the age 18 to 55 years.

Moderna has reported the dosing of the first subject in a Phase I HVTN 302 clinical trial of an investigational human immunodeficiency virus (HIV) trimer messenger ribonucleic acid (mRNA) vaccine, mRNA-1574.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The Division of AIDS (DAIDS) of the US National Institutes of Health (NIH) unit National Institute of Allergy and Infectious Diseases (NIAID) is sponsoring and funding the trial. 

The multicentre, open-label, randomised trial will analyse the safety and immunogenicity of the vaccines by enrolling nearly 100 HIV-negative adults of the age 18 to 55 years.

Scripps Research was awarded NIAID (DAIDS) Consortium for HIV/AIDS Vaccine Development (CHAVD) funding to develop native-like HIV trimers and produce the mRNA-1574 vaccine.

The company anticipates the soluble and membrane-bound HIV envelope trimer mRNA vaccines to be safe and well-tolerated in people who are not HIV infected and induce autologous neutralising antibodies.

Moderna president Stephen Hoge said: “Developing a vaccine regimen that induces sustained protective levels of HIV neutralising antibodies in humans has been difficult to achieve. 

“With the launch of our second HIV vaccine trial, we are advancing our strategy to utilise multiple mRNA encoded native-like HIV trimers and leverage the power of our mRNA platform to accelerate the discovery of a protective HIV vaccine. 

“This study is another step in our fight against HIV, as well as other latent viruses such as our recently launched studies in CMV and EBV.”

Currently, the company is progressing two HIV preventative vaccine approaches based on germline targeting and immune-focusing techniques. 

Apart from the mRNA-1574 vaccine trial, Moderna is collaborating on HIV vaccine antigens, mRNA-1644 and mRNA-1644v2-Core. 

These HIV vaccine antigens are being assessed in an IAVI-sponsored Phase I trial, which is supported by the Bill & Melinda Gates Foundation.

The latest development comes after the company dosed the first subject in Phase II trial of its Omicron-specific bivalent booster candidate, mRNA-1273.214.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena